Nasus Pharma Ltd. (NSRX)

Nasus Pharma Statistics

Total Valuation

Nasus Pharma has a market cap or net worth of $27.52 million. The enterprise value is $23.35 million.

Market Cap	27.52M
Enterprise Value	23.35M

Important Dates

The last earnings date was Friday, March 20, 2026, before market open.

Earnings Date	Mar 20, 2026
Ex-Dividend Date	n/a

Share Statistics

Nasus Pharma has 11.71 million shares outstanding. The number of shares has increased by 15.11% in one year.

Current Share Class	11.71M
Shares Outstanding	11.71M
Shares Change (YoY)	+15.11%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	34.01%
Owned by Institutions (%)	4.93%
Float	6.14M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	7.65
P/TBV Ratio	9.94
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.24, with a Debt / Equity ratio of 0.04.

Current Ratio	2.24
Quick Ratio	1.98
Debt / Equity	0.04
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-107.15%
Return on Invested Capital (ROIC)	-415.31%
Return on Capital Employed (ROCE)	-172.62%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	n/a
Profits Per Employee	-$2.93M
Employee Count	2
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	4.61
200-Day Moving Average	n/a
Relative Strength Index (RSI)	35.49
Average Volume (20 Days)	484,965

Short Selling Information

The latest short interest is 11,380, so 0.10% of the outstanding shares have been sold short.

Short Interest	11,380
Short Previous Month	5,224
Short % of Shares Out	0.10%
Short % of Float	0.19%
Short Ratio (days to cover)	2.80

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-4.90M
Pretax Income	-5.81M
Net Income	-5.86M
EBITDA	n/a
EBIT	-4.90M
Earnings Per Share (EPS)	-$0.73

Balance Sheet

The company has $4.29 million in cash and $118,000 in debt, with a net cash position of $4.17 million or $0.36 per share.

Cash & Cash Equivalents	4.29M
Total Debt	118,000
Net Cash	4.17M
Net Cash Per Share	$0.36
Equity (Book Value)	2.77M
Book Value Per Share	0.31
Working Capital	2.69M

Cash Flow

In the last 12 months, operating cash flow was -$4.92 million and capital expenditures -$14,000, giving a free cash flow of -$4.93 million.

Operating Cash Flow	-4.92M
Capital Expenditures	-14,000
Depreciation & Amortization	n/a
Net Borrowing	n/a
Free Cash Flow	-4.93M
FCF Per Share	-$0.42

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Nasus Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-15.11%
Shareholder Yield	-15.11%
Earnings Yield	-21.28%
FCF Yield	-17.92%

Analyst Forecast

The average price target for Nasus Pharma is $19.67, which is 737.02% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$19.67
Price Target Difference	737.02%
Analyst Consensus	Strong Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2